Pivotal trials and novel combinations have started, but four programmes seem to have been discontinued.
ApexOnco Front Page
Recent articles
Varseta-M efficacy wanes, but more than justifies a pivotal trial.
Meanwhile, Tecvayli stalls, but J&J still hopes for growth.
OncoC4’s AI-081 features among the industry’s latest first-in-human trial initiations.
The company reckons it can outdo Bristol’s relatlimab in first-line NSCLC.
Aktis scores a plenary, as do Tyra’s FGFR3 inhibitor and Arcus’s HIF-2α contender.
The group will present the first clinical data on its KRAS G12D-selective project RMC-9805.
The group reports responses with its CD123-targeting ADC, but cash is running short.
